AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06467526
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)
Trial: NCT06182267
Drug: L Arginine
RxNorm normalized name: ACETYL ARGININE
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: toothpaste
Trial: NCT05379959
Drug: placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given a placebo capsule that will only contain lactose.
Trial: NCT05732883
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04778800
Drug: LM-first line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
Trial: NCT04778800
Drug: LM-second line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
Trial: NCT05943080
Drug: IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)
RxNorm normalized name: Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is applied to the anatomical space between the posterior capsule and the popliteal artery with the help of USG.
Trial: NCT05318820
Drug: HMPL-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
Trial: NCT05478174
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK3486 for induction of general anesthesia
Trial: NCT06286423
Drug: Control/Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treated subjects will take 0.6mg of placebo 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of placebo1x per day (or every other day if kidney disease is present) for 76 +/1 days.
Trial: NCT06358014
Drug: Fematon (estradiol/estradiol-norethindrone acetate combination tablet package)+SSRIs
RxNorm normalized name: estradiol / norethindrone acetate Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the combination group, eligible subjects will receive 1 tablet/day of estradiol/estradiol-norethindrone acetate combination tablet for 8 weeks. The estradiol/estradiol-norethindrone acetate combination tablet will be taken orally before bedtime, 1 tablet/day (trade name: Fematon, Abbott Laboratories, USA, this product is a combination package, with estradiol 1 mg in the first 14 days of each treatment cycle, and estradiol 1 mg and norethindrone acetate 10 mg in the last 14 days of each treatment cycle). This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram.
Trial: NCT06358014
Drug: SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs. During the study, medication doses will be quantitatively adjusted based on the results of each visit assessment combined with drug concentrations.
Trial: NCT05195528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally via capsule
Trial: NCT06533605
Drug: SSGJ-706
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific antibody
Trial: NCT06237556
Drug: Melatonin 5 MG
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
Trial: NCT04620148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo concentrate solution
Trial: NCT06386705
Drug: TSN084
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Trial: NCT05403229
Drug: Systemic Steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups receive a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.
Trial: NCT05098509
Drug: RAD011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol Oral Solution (containing synthetic cannabidiol)
Trial: NCT05098509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for RAD011
Trial: NCT05042284
Drug: Non-enteric coated pancreatic enzyme preparation
RxNorm normalized name: Oryctolagus cuniculus pancreatin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
Trial: NCT04999527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
Trial: NCT04844528
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral nicotinamide 500 mg twice daily (BID)
Trial: NCT04844528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo twice daily for first year. Cross over to oral nicotinamide 500 mg twice daily (BID) for year two.
Trial: NCT05501743
Drug: Intra-articular injection of microfat and PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
Trial: NCT05579769
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
Trial: NCT05579769
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
Trial: NCT05579769
Drug: Bone marrow infusion
RxNorm normalized name: Sus scrofa bone marrow preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 0
Trial: NCT05956509
Drug: Placebo for ABBV-950
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) Injection
Trial: NCT00017758
Drug: Pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00017758
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05902208
Drug: Antiviral treatment with conventional non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
Trial: NCT05902208
Drug: Placebo with conventional non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
Trial: NCT05855863
Drug: Ginkgo Ketone Ester Tablets
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
Trial: NCT05855863
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
Trial: NCT04545515
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination (FDC) tablets for oral administration.
Trial: NCT06252441
Drug: Rectal Diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Rectal Diclofenac Before ERCP
Trial: NCT06252441
Drug: Oral N-acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
Trial: NCT01384435
Drug: KPS-0373
RxNorm normalized name: Draxxin KP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01384435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04798716
Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose 2 X 10\^9, 4 X 10\^9, 8 X 10\^9/mL
Trial: NCT05874622
Drug: VC005 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 groups repeat administration for 4 weeks
Trial: NCT05874622
Drug: VC005 Tablets Placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 placebo groups repeat administration for 4 weeks
Trial: NCT05669872
Drug: Ferric Carboxymaltose 50Mg/Ml Inj 20Ml
RxNorm normalized name: FERRIC CARBOXYMALTOSE 50MG/ML INJ 20ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ferric carboxymaltose 1000mg, fixed dose for intervention group
Trial: NCT05630807
Drug: Bepirovirsen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen will be administered.
Trial: NCT06008925
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
Trial: NCT04902235
Drug: Experimental: CRH administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
Trial: NCT04902235
Drug: Control: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
Trial: NCT00002082
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05628740
Drug: 3 mg NOC-100 (via nebulizer)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
Trial: NCT05628740
Drug: 1 mg NOC-110 (via DPI) [1x 1 mg capsule]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
Trial: NCT05628740
Drug: Placebo (via DPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
Trial: NCT05628740
Drug: Placebo (via DPI) [2x Placebo capsules]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
Trial: NCT04982029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT06207682
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally via tablets
Trial: NCT04772248
Drug: TNF Inhibitor
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First eligible prescription for treating rheumatoid arthritis (RA)
Trial: NCT05887999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT06316973
Drug: CS-1103
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-1103 for infusion
Trial: NCT06316973
Drug: Sterile Saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Saline for Injection
Trial: NCT05120219
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
Trial: NCT05120219
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
Trial: NCT05120219
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single and multiple doses of HR20033 FDC tablet
Trial: NCT05784701
Drug: TSCV (Full-strength)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSCV (Full-strength)
Trial: NCT05784701
Drug: TSCV (Half-strength)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSCV (Half-strength)
Trial: NCT05784701
Drug: Typbar-TCV
RxNorm normalized name: Typhoid conjugate vaccine (TCV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typbar-TCV
Trial: NCT05784701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05287256
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be orally self-administered by study participants
Trial: NCT05015309
Drug: SH3765 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
Trial: NCT05287256
Drug: Vaporized Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be self-administered by study participants using a vaporizer
Trial: NCT05669092
Drug: XELIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
Trial: NCT05669092
Drug: FOLFRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
Trial: NCT05915026
Drug: Gadoquatrane (BAY1747846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Trial: NCT05473533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; formulated as solution for inhalation without active substance.
Trial: NCT05473533
Drug: PRS-220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRS-220; formulated as solution for inhalation.
Trial: NCT05155969
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.
Trial: NCT05836610
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous bolus hydrocortisone therapy during hypothermia treatment
Trial: NCT04750122
Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of chemotherapy is based on the PTC drug sensitivity results.
Trial: NCT06453291
Drug: NSAIDs (Nonsteroidal Anti-Inflammatory Drugs):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Objective: To reduce pain and inflammation associated with chronic low back pain.~Medications: Ibuprofen, Naproxen, or Diclofenac.~Dosage:~Ibuprofen: 400-600 mg every 6-8 hours as needed. Naproxen: 250-500 mg twice daily as needed. Diclofenac: 50 mg three times daily as needed. Administration: Oral tablets. Duration: Daily use as prescribed, for the duration of the study. Monitoring: Regular follow-up visits to monitor pain levels, side effects, and adherence.
Trial: NCT06267066
Drug: Vaseline Topical Product
RxNorm normalized name: Vaseline Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient
Trial: NCT06388551
Drug: LY03017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, administered orally
Trial: NCT06388551
Drug: LY03017-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, administered orally
Trial: NCT06368063
Drug: Huaier granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
Trial: NCT05074550
Drug: PPMX-T003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
Trial: NCT04865835
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of placebo
Trial: NCT05304559
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
Trial: NCT05168007
Drug: WID-RGC20(Cariprazine) 3mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
Trial: NCT05168007
Drug: WID-RGC20(Cariprazine) 6mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
Trial: NCT05168007
Drug: Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo comparator is administered during the double-blind treatment period(6 weeks).
Trial: NCT06274554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsules will be used as a comparator.
Trial: NCT04688164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT05137795
Drug: ZYESAMI™ (aviptadil acetate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
Trial: NCT05137795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Inhalation
Trial: NCT06230354
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection
Trial: NCT06158555
Drug: 250 ML NaCl 4.5 MG/ML Injection
RxNorm normalized name: 250 ML NaCl 4.5 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus 250 ml crystalloid. Usually 0.9% saline or compound sodium lactate solution at discretion of attending clinician
Trial: NCT06184334
Drug: Solfenacin
RxNorm normalized name: solfenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pills taken once day
Trial: NCT05827796
Drug: IN10018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.